USFDA completes inspection of JBCPL without observations

The USFDA has successfully completed the inspection of JB Chemicals & Pharmaceuticals Limited's (JBCPL) newly set up and commissioned solid oral dosage formulation manufacturing facility at Panoli, Gujarat.

At the end of the inspection, no objectionable observations were found and hence no Form 483 was issued, informed the company in a filing to the exchanges. The said inspection was carried out from June 24 to June 28, 2019. The facility has a capacity of 2 billion tablets per annum, which is expandable to 9 billion tablets per annum. This new facility has already been approved by EU authorities in February 2019 and classified as cGMP compliant.

The new facility will augment the Company's manufacturing capacity for regulated markets like USA and EU as and when the product approvals are received.

JBCPL is engaged in manufacturing a range of innovative speciality products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules.

On Wednesday, stock of JB Chemicals opened at Rs. 373.35 per share. During the morning session, the stock initially touched Rs. 380.65 level and later dipped by 1.9 per cent to Rs. 365.80 per share.